Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms

Pharmazie

Volumn 68, Issue 2, 2013, Pages 124-128

  Zhou, Quan ^a   Ruan, Zou Rong ^a   Jiang, Bo ^a   Yuan, Hong ^a   Zeng, Su ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; SIMVASTATIN; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; CARRIER PROTEIN; CYP2C9 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; TUMOR PROTEIN; UNSPECIFIC MONOOXYGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; GENE DOSAGE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; ASIAN; GENETIC POLYMORPHISM; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; CYTOCHROME P-450 CYP3A; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDICATORS AND REAGENTS; MALE; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SIMVASTATIN; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875867323     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2676     Document Type: Article

References (14)

1. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2009) Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics 10: 1743-1751.
2. Chen B, Fang J, Zhang W, Jin Z, Yu Z, Cai W (2009) Detection of C1236T, G2677T/A, and C3435T polymorphism of MDR1by amplification refractory mutation system PCR. J Clin Lab Anal 23: 110-116.
3. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2005) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78: 551-558.
4. Gonzalez TP, Mucenic T, Brenol JC, Xavier RM, Schiengold M, Chies JA (2008) ABCB1 C1236T, G2677T/A and C3435T polymorphisms in systemic lupus erythematosus patients. Braz J Med Biol Res 41: 769-772.
5. Hu M, Mak VW, Tomlinson B (2012) Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics.
6. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M (2008) ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84: 457-461.
7. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M (2009) Different effects of the ABCG2 c.421C >A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10: 1617-1624.
8. Kim KA, Park PW, Lee OJ, Kang DK, Park JY (2007) Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 47: 87-93.
9. Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, Hidalgo IJ (2011) Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39: 1196-1202.
10. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14: 429-440.
11. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16: 873-879.
12. Sortica VA, Fiegenbaum M, Lima LO, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2012) SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Clin Chem Lab Med 50: 441-448.
13. Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Bio Chem 276: 35669-35675.
14. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, Liu ZQ, Wang D, Huang YF, Zhou HH, Sun ZQ (2007) Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol Sin 28: 1693-1697.